Page last updated: 2024-12-10
compound 348u87
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
compound 348U87: structure given in first source; antiherpes cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 3006985 |
| MeSH ID | M0190136 |
Synonyms (12)
| Synonym |
|---|
| 1-(2-chlorophenyl)-3-[(1-pyridin-2-ylethylideneamino)carbamothioylamino]thiourea |
| carbonothioic dihydrazide, 2-(((2-chlorophenyl)amino)thioxomethyl)-21-(1-(2-pyridinyl)ethylidene)- |
| 90ov2wy8jf , |
| bw 348u87 |
| 2-actylpyridine 5-((2-chloroanilino)thiocarbonyl)thiocarbonohydrazone |
| 348 u87 |
| compound 348u87 |
| unii-90ov2wy8jf |
| carbonothioic dihydrazide, 2-(((2-chlorophenyl)amino)thioxomethyl)-2'-(1-(2-pyridinyl)ethylidene)- |
| 2-(((2-chlorophenyl)amino)thioxomethyl)-2'-(1-(2-pyridinyl)ethylidene)carbonothioic dihydrazide |
| n-(2-chlorophenyl)-2-({(2e)-2-[1-(2-pyridinyl)ethylidene]hydrazino}carbothioyl)hydrazinecarbothioamide |
| PD067974 |
Research Excerpts
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| " We treated 10 human immunodeficiency virus-infected patients with acyclovir-resistant anogenital herpes simplex virus infection with a topical preparation of 348U87 (3%) in combination with acyclovir (5%) in an open-labelled study." | ( Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir. Corey, L; Delehanty, J; Hill, E; Safrin, S; Schacker, T, 1993) | 0.29 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " None of the novel ribonucleotide reductase inactivators was hematologically toxic to rats following oral dosing at 60 mg/kg/day for 30 days." | ( Inactivators of herpes simplex virus ribonucleotide reductase: hematological profiles and in vivo potentiation of the antiviral activity of acyclovir. Blumenkopf, TA; Ellis, MN; Lobe, DC; Spector, T; Szczech, GM, 1992) | 0.28 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.37
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.37) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (28.57%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (71.43%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||